Furthermore, CSC-intrinsic PD-L1 pathways take a nonnegligible role in cancer progression and metastasis in an immune independent way, adding more complexity to the mixed response of cancer patients to PD-1/PD-L1 blockade. This evidence concerns the gene PDCD1 and cancer.